Systematic review assesses hydroxyurea's effects on vaso-occlusive crises and haemoglobin levels in Indian SCD patients, suggesting significant benefits.
Key Points
Hydroxyurea significantly increased foetal haemoglobin levels in Indian sickle cell disease patients.
The treatment reduced vaso-occlusive crises frequency by 79-93%, indicating promising efficacy.
Hospitalizations and anaemia improved with hydroxyurea, demonstrating beneficial outcomes for patients.
Safety profile shows generally mild, reversible side effects among those treated with hydroxyurea.